Application of Fluorescence- and Bioluminescence-Based Biosensors in Cancer Drug Discovery DOI Creative Commons

Tynan Kelly,

Xiaolong Yang

Biosensors, Год журнала: 2024, Номер 14(12), С. 570 - 570

Опубликована: Ноя. 24, 2024

Recent advances in drug discovery have established biosensors as indispensable tools, particularly valued for their precision, sensitivity, and real-time monitoring capabilities. The review begins with a brief overview of cancer discovery, underscoring the pivotal role advancing research. Various types employed are then explored, particular emphasis on fluorescence- bioluminescence-based technologies such FRET, TR-FRET, BRET, NanoBRET, NanoBiT. These enabled breakthrough discoveries, including identification Celastrol novel YAP-TEAD inhibitor through NanoBiT-based screening, development TR-FRET assays that successfully identified Ro-31-8220 SMAD4R361H/SMAD3 interaction inducer. integration high throughput screening validation compounds is examined, highlighting successful applications LATS revealed VEGFR an upstream regulator Hippo signaling pathway. Real-time cellular responses has yielded invaluable insights into cell pathways, demonstrated by NanoBRET detecting RAF dimerization HiBiT systems protein degradation dynamics. addresses challenges linked to biosensor applications, maintaining stability complex tumor microenvironments achieving consistent sensitivity HTS applications. Emerging trends discussed, integrating artificial intelligence advanced nanomaterials enhanced performance. In conclusion, this offers comprehensive analysis dynamic field, presenting quantitative evidence impact potential revolutionize targeted treatments.

Язык: Английский

Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of Neuroendocrine Bladder Cancer DOI Creative Commons
Dongbo Xu, Qiang Li

Опубликована: Март 6, 2025

Neuroendocrine bladder cancer (NEBC) is a rare but highly aggressive cancer, representing approximately 1% of urinary cancer. The most common NEBC small cell (SCBC), characterized by high rates recurrence, chemotherapy resistance, and early mortality. SCBC histologically identical to lung (SCLC) remains significantly understudied. Advances in next-generation sequencing techniques have partially elucidated the molecular characteristics identified druggable targets. This review compiles recent studies on human samples, summarizing key findings their genomic alterations subtyping. Notably, it highlights specific mutations TERT promoter epigenetic modifiers NEBC, as well subtyping based lineage-specific transcription factors, including ASCL1, NEUROD1, POU2F3. Furthermore, this explores significant tumor heterogeneity cellular plasticity observed discusses its origin potential therapeutic targets (MET inhibitor or DLL3) preclinical models. Emerging evidence suggests that may share with urothelial carcinoma (UC), arising from UC precursor. Advancing our understanding tumorigenesis identifying will enhance treatment outcomes for patients NEBC.

Язык: Английский

Процитировано

0

Modern tumor imaging models for rodents: potential and prospects in translational medicine DOI Creative Commons
Anastasia A. Fadeeva,

ZM Osipova,

TV Chepurnykh

и другие.

Bulletin of Russian State Medical University, Год журнала: 2025, Номер 2025(2)

Опубликована: Март 1, 2025

Rodent neoplastic process models are extensively used in pre-clinical practice to assess the dynamics of tumor development and test anti-cancer drugs, which ensures flexibility choosing both basic advanced personalized for researchers. Various modern model imaging methods considered, including fluorescence bioluminescence imaging, enable comprehensive assessment, from qualitative evaluation vivo monitoring. We believe that autonomous bioluminescent systems mammalian cells will provide new possibilities noninvasive animal physiological processes, long-term monitoring progression.

Язык: Английский

Процитировано

0

Practical implementation and impact of the 4R principles in ethnopharmacology: Pursuing a more humane approach to research DOI Creative Commons
Jimin Liu,

Xiang Zai,

Xiyan Tian

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 28, 2025

Ethnopharmacology, a discipline focused on studying the medicinal use of natural materials by humans, plays crucial role in addressing challenges modern drug development. However, traditional 3R principle-Replacement, Reduction, and Refinement-have limitations guiding ethical management animal experimentation, conducting studies, utilizing animal-derived ethnopharmacological research. To address these gaps, field has introduced 4R principles, which expand original framework adding "Responsibility." The Responsibility principle highlights obligation researchers to consider welfare experimental animals during all procedures. It calls for take accountability their actions decisions, ensuring that they actively protect exhibit empathy across species. This reinforces foundation implement principles effectively, this article explores dimensions Refinement, Replacement, detail. For strategies include minimizing developing optimized, efficient designs, creating tissue banks recycle samples, improving success rates modeling. These efforts collectively aim enhance standards while advancing scientific outcomes. In terms goal is minimize distress pain environment, refining operational procedures, strict control experiments under anesthesia, prioritizing non-invasive or minimally invasive techniques data collection. reduce need exploring alternative solutions. includes substituting vitro vivo ones, using 3D organoids replace organs, applying deep learning technologies ways decrease use. focuses enhancing researchers' obligations toward welfare. can be achieved regulations policies governing providing training technical personnel, promoting awareness practices. introduction implementation provide valuable guidance conduct experimentation research, offering new insights methodologies support responsible studies.

Язык: Английский

Процитировано

0

Application of Fluorescence- and Bioluminescence-Based Biosensors in Cancer Drug Discovery DOI Creative Commons

Tynan Kelly,

Xiaolong Yang

Biosensors, Год журнала: 2024, Номер 14(12), С. 570 - 570

Опубликована: Ноя. 24, 2024

Recent advances in drug discovery have established biosensors as indispensable tools, particularly valued for their precision, sensitivity, and real-time monitoring capabilities. The review begins with a brief overview of cancer discovery, underscoring the pivotal role advancing research. Various types employed are then explored, particular emphasis on fluorescence- bioluminescence-based technologies such FRET, TR-FRET, BRET, NanoBRET, NanoBiT. These enabled breakthrough discoveries, including identification Celastrol novel YAP-TEAD inhibitor through NanoBiT-based screening, development TR-FRET assays that successfully identified Ro-31-8220 SMAD4R361H/SMAD3 interaction inducer. integration high throughput screening validation compounds is examined, highlighting successful applications LATS revealed VEGFR an upstream regulator Hippo signaling pathway. Real-time cellular responses has yielded invaluable insights into cell pathways, demonstrated by NanoBRET detecting RAF dimerization HiBiT systems protein degradation dynamics. addresses challenges linked to biosensor applications, maintaining stability complex tumor microenvironments achieving consistent sensitivity HTS applications. Emerging trends discussed, integrating artificial intelligence advanced nanomaterials enhanced performance. In conclusion, this offers comprehensive analysis dynamic field, presenting quantitative evidence impact potential revolutionize targeted treatments.

Язык: Английский

Процитировано

1